HAYA Therapeutics Revenue

Biotechnology Research • Route De La Corniche 5B, SuperLab Suisse - Batiment Alanine, Switzerland • 51-100 Employees

HAYA Therapeutics revenue & valuation

Annual revenue	$4,962,190
Revenue per employee	$86,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$15,900,000
Total funding	$1,070,000,000

Key Contacts at HAYA Therapeutics

Rabab Nasrallah

Member Board Of Directors

Daniel Blessing

Co-Founder, Chief Technology Officer And Board Director

Carsten Merkwirth

Senior Director, Biomarkers

Marco Mina

Director, Computational Biology

Fanny Kling

Director, Regulatory Science

Rudi Micheletti

Director Of Biology And Functional Genomics

Company overview

Headquarters	Route De La Corniche 5B, SuperLab Suisse - Batiment Alanine, Switzerland
Website	hayatx.com
NAICS	541714
SIC	873
Keywords	Fibrosis, Lncrna, Genomic Medicines
Founded	2019
Employees	51-100
Socials

HAYA Therapeutics Email Formats

HAYA Therapeutics uses 3 email formats. The most common is {first initial}.{last name} (e.g., j.doe@hayatx.com), used 47.6% of the time.

Format	Example	Percentage
{first initial}.{last name}	j.doe@hayatx.com	47.6%
{first name}.{last name}	john.doe@hayatx.com	42.9%
{first initial}	j@hayatx.com	9.5%

About HAYA Therapeutics

HAYA Therapeutics is a precision medicines company developing RNA-guided programmable therapeutics targeting the regulatory genome for serious health conditions including cardiovascular disease and cancer. The company is using its innovative cell-state modifying platform to gain novel insights into the biology of long non-coding RNAs (lncRNAs), the ‘dark genomes’ information processing features and ‘source code’. HAYA’s lead therapeutic candidate is HTX-001, an antisense oligonucleotide targeting Wisper, which is a tissue and cell-specific cardiac lncRNA known to play a role in heart failure. The company is also developing a pipeline of lncRNA-targeting candidates for the cell-specific treatment of diseases in other tissues, including the lungs and the microenvironment of solid tumor cancers. Headquartered at the life sciences park Biopôle in Lausanne, Switzerland with laboratory facilities at Lilly Gateway Labs, powered by Alexandria, in San Diego, HAYA is led by a world-class team of experts in programmable and precision RNA-targeted therapeutics and is supported by a strong investor consortium. HAYA’s mission is to identify and develop breakthrough disease-modifying therapeutics with the potential for greater efficacy, safety, and accessibility than existing treatments.

Employees by Management Level

Total employees: 51-100

Seniority

Employees

Entry

Manager

Senior

Employees by Department

HAYA Therapeutics has 29 employees across 10 departments.

Departments

Number of employees

Funding Data

Explore HAYA Therapeutics's funding history, including investment rounds, total capital raised, and key backers.

Funding Date	Round	Amount
2022-03-09	3	$5,000,000
2024-10-04	1	N/A
2024-10-04	15	$1,000,000,000
2025-06-08	4	$65,000,000
2025-10-01	9	N/A

Funding Insights

$1,070,000,000

Total funding amount

Number of funding rounds

HAYA Therapeutics Tech Stack

Discover the technologies and tools that power HAYA Therapeutics's digital infrastructure, from frameworks to analytics platforms.

Cloudflare

CDN

Google Hosted Libraries

CDN

FlippingBook

Widgets

jQuery

JavaScript libraries

Google Tag Manager

Tag managers

Apple iCloud Mail

Webmail

HTTP/3

Miscellaneous

HSTS

Security

Open Graph

Miscellaneous

Lucide

Font scripts

Webflow

Page builders

Google Analytics

Analytics

Frequently asked questions

HAYA Therapeutics is located in Route De La Corniche 5B, SuperLab Suisse - Batiment Alanine, CH.

HAYA Therapeutics generates an estimated annual revenue of $4,962,190. This revenue figure reflects the company's market position and business performance in its industry.

HAYA Therapeutics has an estimated valuation of $15,900,000. This valuation is calculated based on industry-standard revenue multiples and reflects the company's growth potential and market positioning.

HAYA Therapeutics was founded in 2019, making it 7 years old. The company has established itself as a significant player in its industry over this time.

HAYA Therapeutics has approximately 51-100 employees. The company continues to grow its workforce to support its business operations and expansion.

HAYA Therapeutics has raised a total of $1,070,000,000 across 5 funding rounds. This investment has helped the company grow and expand its operations.